Rhythm Pharmaceuticals Inc (RYTM)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $7.97B
Last updated: Nov 17, 2026 at 4:35 PM ET
Rhythm Pharmaceuticals Inc (RYTM) Stock Chart
Rhythm Pharmaceuticals (RYTM) has a latest price of $116.61 on Nov 17, 2026, 4.6% below its 52-week high of $122.20. Its price rose 17.3% over the past 12 months. The month-end price rose 261.9% since Oct 2017, a compound annual rate of 15.4%.
Price Chart
From Oct 2017 to Oct 2026, its highest month-end close was $113.76 in Oct 2025 and its lowest $3.44 in May 2022, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart RYTM with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for RYTM.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price rose 0.8%, and over 6 months it rose 33.7%. The month-end price rose 300.6% over the 3 years through Oct 2026, a compound annual rate of 58.8%.
| Period | Change |
|---|---|
| 1 month | +32.2% |
| 3 months | +0.8% |
| 6 months | +33.7% |
| 12 months | +17.3% |
| 12 months, with dividends | +17.3% |
| Period | Change | Per year |
|---|---|---|
| 3 years | +300.6% | +58.8% |
| 5 years | +704.3% | +51.7% |
| Since Oct 2017 | +261.9% | +15.4% |
Price by Year
Its best calendar year was 2022, when the price rose 191.8%, and its weakest was 2021, when it fell 66.4%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $92.57 | -13.5% |
| 2025 | $107.04 | +91.2% |
| 2024 | $55.98 | +21.8% |
| 2023 | $45.97 | +57.9% |
| 2022 | $29.12 | +191.8% |
| 2021 | $9.98 | -66.4% |
| 2020 | $29.73 | +29.5% |
| 2019 | $22.96 | -14.6% |
| 2018 | $26.88 | -7.5% |
Trading Range
The price is 19.9% above its 50-day average of $97.27 and 19.8% above its 200-day average of $97.31.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $116.61 | |
| 52-week high | $122.20 | -4.6% |
| 52-week low | $74.50 | +56.5% |
| 50-day average | $97.27 | +19.9% |
| 200-day average | $97.31 | +19.8% |
Price Risk
Over 3 years, its largest fall from a peak was 35.5%.
| Measure | Value |
|---|---|
| 1-year beta | 1.20 |
| Largest fall, 1 year | -35.5% |
| Largest fall, 3 years | -35.5% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About RYTM
What is RYTM's 1-year price change?
Rhythm Pharmaceuticals's price rose 17.3% over the past 12 months. With dividends included, the 12-month total return was 17.3%.
What is RYTM's 5-year price change?
Rhythm Pharmaceuticals's month-end price rose 704.3% over the 5 years through Oct 2026, a compound annual rate of 51.7%. These figures leave out dividends.
What is RYTM's 52-week high and low?
Rhythm Pharmaceuticals's 52-week high is $122.20 and its 52-week low is $74.50. Its latest price of $116.61 on Nov 17, 2026 is 4.6% below the high.
What is RYTM's beta?
Rhythm Pharmaceuticals's 1-year beta against the S&P 500 is 1.20, so its price has moved about in line with the market over the past year. Its largest fall from a peak over the past year was 35.5%.
Is the RYTM chart free?
Yes. Advanced Charting for RYTM is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
RYTM pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors